Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Taysha Gene Therapies Inc
TSHA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$3.65
0.03
0.83%
Dern. MÀJ: Oct 19, 9:30 AM
$3.65
0.03
0.83%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Taysha Gene Therapies Financials
Taysha Gene Therapies (TSHA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 50 percent decrease over losses of $(0.08) per share from
Benzinga Newsdesk
PRO
Taysha Gene Therapies Q4 EPS $(0.12) Misses $(0.10) Estimate, Sales $5.485M Beat $1.889M Estimate.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 23.71 percent. This is a 71.43 percent decrease over losses of $(0.07) per
Benzinga Newsdesk
Earnings Scheduled For March 19, 2026
Benzinga Insights
PRO
Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year.
Benzinga Newsdesk
